Linagliptin

Linagliptin
Linagliptin
Systematic (IUPAC) name
8-[(3R)-3-aminopiperidin-1-yl]-7-(but-2-yn-1-yl)-3- methyl-1-[(4-methylquinazolin-2-yl)methyl]-3,7-dihydro-1H-purine-2,6-dione
Clinical data
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a611036
Licence data US FDA:link
Pregnancy cat. B(US)
Legal status -only (US)
Routes Oral
Identifiers
CAS number 668270-12-0
ATC code A10BH05
PubChem CID 10096344
UNII 3X29ZEJ4R2 YesY
KEGG D09566 YesY
Chemical data
Formula C25H26N8O2 
Mol. mass 472.54 g/mol
 YesY(what is this?)  (verify)

Linagliptin (BI-1356, trade names Tradjenta and Trajenta) is a DPP-4 inhibitor developed by Boehringer Ingelheim for treatment of type II diabetes.

Linagliptin (once-daily) was approved by the US FDA on 2 May 2011 for treatment of type II diabetes.[1] It is being marketed by Boehringer Ingelheim and Lilly.

Mechanism of action

Linagliptin is an inhibitor of DPP-4, an enzyme that degrades the incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Both GLP-1 and GIP increase insulin biosynthesis and secretion from pancreatic beta cells in the presence of normal and elevated blood glucose levels. GLP-1 also reduces glucagon secretion from pancreatic alpha cells, resulting in a reduction in hepatic glucose output. Thus, linagliptin stimulates the release of insulin in a glucose-dependent manner and decreases the levels of glucagon in the circulation.

Clinical trials

Results in 2010 from a Phase III clinical trial of linagliptin showed that the drug can effectively reduce blood sugar.[2]

References

  • H. Spreitzer (September 1, 2008). "Neue Wirkstoffe - BI-1356" (in German). Österreichische Apothekerzeitung (18/2008): 918. 
  • Wang, Y, Serradell, N, Rosa, E, Castaner, R (2008). "BI-1356". Drugs of the Future 33 (6): 473–477. doi:10.1358/dof.2008.033.06.1215244.